EGFR and non-small cell lung carcinoma: METTL1 has also been implicated in resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs), a major clinical challenge in non-small cell lung cancer (NSCLC) despite durable complete responses in some patients (25).